Erianin Salts, Their Preparation Methods and Pharmaceutical Compositions Containing the Same
AssigneeThe Jiang Cell Biomedical Research Co., Ltd.
InventorsYiping Li, Ning Li
Life of this patent
Estimating the term…
Abstract
This invention relates to a kind of Erianin salt and the preparing process thereof. The said Erianin salt is a compound with the following general formula (I), wherein R is the salt formed by monobasic acid radical of inorganic oxacid combining with metals, ammonium salts, organic amine. This invention also relates to a pharmaceutical composition comprising Erianin salt. Compared with Erianin, the said Erianin salt has far better solubility, which can improve the bioavailability and show better antineoplastic efficacy.
Claims23
A pharmaceutically acceptable salt of Erianin represented by the following general formula (I):
- wherein:
- R is a salt formed by monobasic acid radical of inorganic oxacid combining with metals, ammonium salts, or organic amine;
- said metals are selected from a group consisting of alkali metals and alkali-earth metals;
- said inorganic oxacid is selected from a group consisting of phosphoric acid, sulphuric acid, sulfurous acid, nitric acid, carbonic acid, hypochoric acid and trifluoroacetic acid.
A process for preparing a pharmaceutically acceptable salt of Erianin comprising the following steps:
- A1. reacting Erianin with phosphorylating agent by phosphorylating reaction of the phenolic hydroxyl in the presence of acid binding agent to form compound (IV), an intermediate of the phosphorylated Erianin, the reacting temperature being 25˜80° C. and the reacting solvent being an inert organic solvent;
- A2. reacting the reaction liquid obtained in step A1 with alkali directly to obtain compound (II), an organic phosphate salt of Erianin;
- The synthetic route is:
- in formula (IV), R4, R5 is independently Obut, Cl or Br respectively, but represents tert-butyl group;
- in formula (II), R1, R2 is independently H, Na, K, or NH4 respectively, and R1 and R2 are not H simultaneously.
A process for preparing a pharmaceutically acceptable salt of Erianin, comprising the following steps:
- B1. under the protection of inert gas, reacting Erianin with dibenzylphosphorite in the presence of acid binding agent by phosphorylating reaction of the phenolic hydroxyl to obtain compound (V), the reaction temperate being −40° C.˜−10° C., the reaction is carried out in inert organic solvent;
- B2. under the protection of inert gas, reacting compound (V) with NaI in the presence of active group protection agent to obtain compound (VI), the reaction is carried out in inert organic solvent;
- B3. reacting compound (VI) with alkali to obtain compound (II),
- the synthetic route is:
- in formula (V), bn represents benzyl group;
- in formula (II), R1, R2 is independently H, Na, K, or NH4 respectively, and R1 and R2 are not H simultaneously.
A process for preparing a pharmaceutically acceptable salt of Erianin, comprising the following steps:
- C1. reacting Erianin with halo sulfonic acid by sulfonylating reaction of phenolic hydroxyl in the presence of acid binding agent to obtain compound (VII), an intermediate of the sulfonylated Erianin, the reacting temperate being −5˜−10° C. and the reacting solvent being an inert organic solvent;
- C2. reacting the reacting liquid obtained in step C1 with alkali directly to prepare compound (III), a sodium sulfate of Erianin;
- the synthetic route is:
- in formula (VII), R6 is Cl or Br;
- in formula (III), R3 is Na, K, or NH4.
Dependencies are inferred from the claim text.